Development and validation of uv-vis specctroscopy method for simultaneous estimation of saxagliptin hydrochloride and metformin hydrochloride in active pharmaceutical ingrident

Journal of Pharmaceutical Education Research 12/2012; 3(2):19-23.

ABSTRACT An analytical method for estimation of Saxagliptin and Metformin in active pharmaceutical ingrident.The method
was validated in terms of linearity, accuracy, precision, specificity, limit of detection and limit of quantitation. The
optimum conditions for the analysis of the drug were established. The maximum wavelength (λ max) of Saxagliptin
and Metformin were found to be 274 nm and 231 nm respectively. The percentage recovery of Saxagliptin and
Metformin were 100.1 and 99.98 respectively. Beer’s laws were obeyed in the concentration range 50-90μg/ml for
Saxagliptin and 2-10μg/ml for Metformin. The linear equation for Saxagliptin and Metformin were found to be
y = 0.012x- 0.462, r² = 0.987 and y = 0.055x - 0.031, r² = 0.990 respectively. Validation was performed as per ICH

1 Follower
242 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: New, simple and convenient potentiometric, spectrofluorimetric and spectrophotometric methods are described for the determination of metformin in pharmaceutical preparations. The potentiometric technique is based on preparation of PVC membrane sensors incorporating metformin–reineckate, and metformin–tungstosilicate ion-pairs as electroactive species with dioctylphthalate and o-nitrophenyloctylether as plasticizers, respectively. A membrane consisting of carboxylated PVC plasticized with dibutylsebacate is also prepared and tested. These sensors give rapid Nernstian response for 10−1–10−5 M metformin at pH range 5–11. The metformin–tungstosilicate based sensor is used in a flow-through sandwich cell for flow injection potentiometric determination of metformin. Graphite sensors coated or doped with metformin–tungstosilicate-PVC, Cu-diethyldithiocarbamate and Ni-diethyldithiocarbamate are also prepared and used for monitoring the titration of the drug with tetraphenyl borate (TPB−), Cu2+ and Ni2+ ions, respectively. The spectrofluorimetric method depends on the reaction of metformin with chrysenequinone in alkaline medium to give a Schiff's base, which upon hydrolysis gives the free base. The latter in the presence of 1-naphthol gives a fluorescent product with excitation and emission maxima at 450 and 520 nm, respectively. The fluorescence–concentration relationship is linear over the range 20–200 μg ml−1 metformin. The proposed spectrophotometric technique involves reaction of metformin with Cu2+ in basic medium to form a Cu–metformin complex. The complex is dissolved in cyclohexylamine and its maximum absorption at 540 nm is measured. Beer's law is obeyed over the range 0.5–2 mg ml−1 metformin. Various cations, some nitrogenous compounds or drug excipients cause no interferences. Results obtained by these techniques are comparable and compare favorably with data obtained using the British Pharmacopoeia method.
    Analytica Chimica Acta 01/1999; 378(1-3):299-311. DOI:10.1016/S0003-2670(98)00500-5 · 4.51 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: The worldwide prevalence of type 2 diabetes mellitus (T2DM) is high, and the chronically poor metabolic control that can result from T2DM is associated with a high risk for microvascular and macrovascular complications. Because of the progressive pathophysiology of T2DM, oral antidiabetic agents often fail to provide sustained glycemic control, indicating the need for new therapies. Saxagliptin (Onglyza™; Bristol-Myers Squibb Company, Princeton, NJ, USA; AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA) is an oral dipeptidyl peptidase-4 inhibitor, recently approved for the treatment of T2DM. Evidence review: Saxagliptin significantly improves glycemic control vs placebo, as demonstrated by decreasing glycated hemoglobin, fasting plasma glucose, and postprandial plasma glucose levels when used as monotherapy; in initial combination with metformin; and as add-on therapy with metformin, sulfonylurea (SU), or thiazolidinedione (TZD). Saxagliptin also significantly improves β-cell function, is weight neutral, has a low risk for hypoglycemia, and has been shown to have cardiovascular safety. Place in therapy: The clinical profile for saxagliptin indicates that it is useful as an adjunct to diet and exercise as first-line monotherapy and in combination with metformin; or as add-on treatment for patients who cannot achieve glycemic control with a combination of diet and lifestyle changes and metformin, SU, or TZD.
    Core Evidence 10/2010; 5:23-37.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The study presents the development and validation of a simple HPLC method for the simultaneous determination of metformin (MTF) and gliclazide (GCZ) in the presence of glibenclamide, in human plasma, for the clinical monitoring of MTF and GCZ after oral administration or for bioequivalence studies. Ion-pair separation followed by UV detection performed on deproteinised plasma samples was chosen for the determination of metformin and gliclazide. The internal standard was glybenclamide. The HPLC method used a Zorbax Eclipse XDB-C18 150x4.6 mm i.d. (5μm) column and analytical guard column 12.5x4.6 mm (5μm), with a gradient elution (1 mL/min) at 40°C column temperature. The mobile phase was acetonitrile: methanol (1:1v/v) and sodium dodecylsulphate 5mM, pH=3.5 with H3PO4 85% and gradient elution. The eluent was monitored at 236 nm. The calibration curve was linear within the range of 0.05-5.00 μg/mL (r2=0.99, n=6). The lowest limit of quantification (LLOQ) was 50 ng/mL for metformin and 49 ng/mL for gliclazide. The proposed method was validated and proved to be adequate for metformin and gliclazide clinical monitoring, bioavailability and bioequivalence studies.
    Farmacia 01/2009; 57(6):728-735. · 1.01 Impact Factor
Show more